p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 499-505

  Roh, Ju Won ^a   Kim, Jae Weon ^b   Park, Noh Hyun ^b   Song, Yong Sang ^b   Park, In Ae ^b   Park, Sang Yoon ^a   Kang, Soon Beom ^b   Lee, Hyo Pyo ^b  

^a National Cancer Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Endometrial cancer; p21; p53; Polymorphism

Indexed keywords

ARGININE; PROLINE; PROTEIN P21; PROTEIN P53; SERINE;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; ALLELES; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 1942476760     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.02.005     Document Type: Article

References (40)

1. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer. 80:1999;827-841.
2. 2002 Annual report of the Korea central cancer registry (2002.1.-2002.12). 2003;Korea Central Cancer Registry, Ministry of Health and Welfare, Republic of Korea.
3. Weber B.L., Nathanson K.L. Low penetrance genes associated with increased risk for breast cancer. Eur. J. Cancer. 36:2000;1193-1199.
4. Lane D.P. Cancer, p53, guardian of the genome. Nature. 358:1992;5-16.
5. Eldeiry W.S., Tokini T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M.et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
6. Honda T., Kato H., Imamura T., Gima T., Nishida J., Sasaki M.et al. Involvement of p53 gene mutations in human endometrial carcinomas. Int. J. Cancer. 53:1993;963-967.
7. Kihana T., Hamada K., Inoue Y., Yano N., Iketani H., Murao S.et al. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer. 76:1995;72-78.
8. Niwa K., Murase T., Morishita S., Hashimoto M., Itoh N., Tamaya T. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detect. Prev. 23:1999;147-154.
9. Matlashewski G.J., Tuck S., Pim D., Lamb P., Schneider J., Crawford L.V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol. 7:1987;961-963.
10. Sjalander A., Birgander R., Hallmans G., Cajander S., Lenner P., Athlin L.et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 17:1996;1313-1316.
11. Papadakis E.N., Dokianakis D.N., Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun. 3:2000;389-392.
12. Buyru N., Tigli H., Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol. Rep. 10:2003;711-714.
13. Esteller M., Garcia A., Martinez-Palones J.M., Xercavins J., Reventos J. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br. J. Cancer. 75:1997;1385-1388.
14. Peller S., Halperin R., Schneider D., Kopilova Y., Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol. Rep. 6:1999;193-197.
15. Ameyaw M.M., Thornton N., McLeod H.L. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J. Natl. Cancer Inst. 92:2000;1947.
16. Sjalander A., Birgander R., Kivela A., Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered. 45:1995;144-149.
17. Kim J.W., Roh J.W., Park N.H., Song Y.S., Kang S.B., Lee H.P. Polymorphism of TP53 codon 72 and the risk of cervical cancer among Korean women. Am. J. Obstet. Gynecol. 184:2001;55-58.
18. Lukas J., Groshen S., Saffari B., Niu N., Reles A., Wen W.H.et al. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am. J. Pathol. 150:1997;167-175.
19. Chedid M., Michieli P., Lengel C., Huppi K., Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly-conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 9:1994;3021-3024.
20. Hachiya T., Kuriaki Y., Ueoka Y., Nishida J., Kato K., Wake N. WAF1 genotype and endometrial cancer susceptibility. Gynecol. Oncol. 72:1999;187-192.
21. Roh J.W., Kim M.H., Kim J.W., Park N.H., Song Y.S., Kang S.B.et al. Polymorphism in codon 31 of p21 and cervical cancer susceptibility. Cancer Lett. 165:2001;59-62.
22. Yair D., Ben Baruch Gk Chetrit A., Friedman T., Hirsh Yechezkei G., Gotliev W.H.et al. p53 and WAF1 polymorphisms in Jewish-Israeli women with epithelial ovarian cancer and its association with BRCA mutations. Br. J. Obstet. Gynaecol. 107:2000;849-854.
23. Mousses S., Ozcelik H., Lee P.D., Malkin D., Bull S.B., Andrulis I.L. Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet. 4:1995;1089-1092.
24. Fan R., Wu M.T., Miller D., Wain J.C., Kelsey K.T., Wiencke J.K.et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 9:2000;1037-1042.
25. Shepherd T., Tolbert D., Benedetti J., Macdonald J., Stemmermann G., Wiest J.et al. Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology. 118:2000;1039-1044.
26. Zehbe I., Voglino G., Wilander E., Delius H., Marongiu A., Edler L.et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 61:2001;608-611.
27. Makni H., Franco E.L., Kaiano J., Villa L.L., Labrecque S., Dudley R.et al. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int. J. Cancer. 87:2000;528-533.
28. Jones M.H., Koi S., Fujimoto I., Hasumi K., Kato K., Nakamura Y. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer. 9:1994;119-123.
29. Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F.et al. Role of a p53 polymorphism in the development of human papillomavirus- associated cancer. Nature. 393:1998;229-234.
30. Helland A., Langerod A., Johnsen H., Olsen A.O., Skovlund E., Borresen-Dale A.L. p53 polymorphism and risk of cervical cancer. Nature. 396:1998;530-531.
31. Hildesheim A., Schiffman M., Brinton L.A., Fraumeni J.F. Jr., Herrero R., Bratti M.C.et al. p53 polymorphism and risk of cervical cancer. Nature. 396:1998;531-532.
32. Josefsson A.M., Magnusson P.K., Ylitalo N., Quarforth-Tubbin P., Ponten J., Adami H.O.et al. P53 polymorphism and risk of cervical cancer. Nature. 396:1998;531.
33. Kim J.W., Lee C.G., Park Y.G., Kim K.S., Kim I.K., Sohn Y.W.et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1. Cancer. 88:2000;2082-2091.
34. Shiohara M.M., el-Deiry W.S., Wada M., Nakamaki T., Takeuchi S., Yang R.et al. Absence of WAF1 mutations in a variety of human malignancies. Blood. 84:1994;3781-3784.
35. Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer. 79:1997;2424-2429.
36. Sjalander A., Birgander R., Rannug A., Alexandrie A.K., Tornling G., Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum. Hered. 46:1996;221-225.
37. WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn. J. Cancer Res. 91:2000;9-15.
38. Konishi R., Sakatani S., Kiyokane K., Suzuki K. Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors. J. Dermatol. Sci. 24:2000;177-183.
39. WAF1/Cip1 polymorphisms in human ovarian cancer. Int. J. Oncol. 15:1999;117-119.
40. ser→arg polymorphism of the WAF-1/Cip-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol. Biomarkers Prev. 4:1995;261-267.